NextCure Signs $820M M&A Deal with Avere Therapeutics, Inc.
NextCure provided a status update on its pending merger with Avere Therapeutics, noting that the SEC has declared its S-4 registration statement effective and a stockholder vote is scheduled for December 9, 2026. The transaction is supported by $820 million in committed financing from a syndicate of healthcare investors to fund the development of Avere's lead inflammatory disease program, AVR-001.
- Value
- $820M
- Counterparty
- Avere Therapeutics, Inc.
“During the third quarter, we continued to execute on the strategic initiatives associated with our proposed merger with Avere Therapeutics. Importantly, total financing commitments supporting the proposed transaction increased to approximately $820 million from a syndicate of leading healthcare-focused and institutional investors. We believe this significant financing commitment reflects strong confidence in Avere's clinical development strategy and the potential of AVR-001, while enhancing the opportunity to create long-term value for NextCure stockholders.”
Michael Richman, President and CEO of NextCure